Wells Fargo’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-169,586
| Closed | -$2.57M | – | 7894 |
|
|
2022
Q3 | $2.57M | Buy |
169,586
+150,219
| +776% | +$1.75M | ﹤0.01% | 2526 |
|
|
2022
Q2 | $145K | Sell |
19,367
-9,510
| -33% | -$67K | ﹤0.01% | 4449 |
|
|
2022
Q1 | $263K | Sell |
28,877
-37,660
| -57% | -$290K | ﹤0.01% | 4831 |
|
|
2021
Q4 | $468K | Buy |
66,537
+11,125
| +20% | +$116K | ﹤0.01% | 4716 |
|
|
2021
Q3 | $632K | Buy |
55,412
+40,947
| +283% | +$599K | ﹤0.01% | 4526 |
|
|
2021
Q2 | $232K | Buy |
14,465
+6,380
| +79% | +$109K | ﹤0.01% | 4963 |
|
|
2021
Q1 | $145K | Sell |
8,085
-71,444
| -90% | -$1.23M | ﹤0.01% | 5315 |
|
|
2020
Q4 | $1.07M | Buy |
79,529
+58,233
| +273% | +$704K | ﹤0.01% | 3977 |
|
|
2020
Q3 | $251K | Sell |
21,296
-10,813
| -34% | -$132K | ﹤0.01% | 4833 |
|
|
2020
Q2 | $474K | Buy |
32,109
+7,393
| +30% | +$109K | ﹤0.01% | 4364 |
|
|
2020
Q1 | $334K | Sell |
24,716
-11,249
| -31% | -$213K | ﹤0.01% | 4344 |
|
|
2019
Q4 | $869K | Buy |
35,965
+612
| +2% | +$12.7K | ﹤0.01% | 3948 |
|
|
2019
Q3 | $680K | Buy |
35,353
+5,981
| +20% | +$137K | ﹤0.01% | 4147 |
|
|
2019
Q2 | $868K | Sell |
29,372
-3,448
| -11% | -$133K | ﹤0.01% | 3964 |
|
|
2019
Q1 | $1.56M | Sell |
32,820
-5,273
| -14% | -$232K | ﹤0.01% | 3555 |
|
|
2018
Q4 | $1.38M | Buy |
38,093
+4,803
| +14% | +$225K | ﹤0.01% | 3597 |
|
|
2018
Q3 | $2.05M | Buy |
33,290
+2,079
| +7% | +$134K | ﹤0.01% | 3388 |
|
|
2018
Q2 | $2.11M | Sell |
31,211
-1,810
| -5% | -$101K | ﹤0.01% | 3417 |
|
|
2018
Q1 | $1.79M | Buy |
33,021
+10,030
| +44% | +$561K | ﹤0.01% | 3461 |
|
|
2017
Q4 | $1.37M | Sell |
22,991
-3,907
| -15% | -$237K | ﹤0.01% | 3678 |
|
|
2017
Q3 | $1.31M | Buy |
26,898
+2,266
| +9% | +$124K | ﹤0.01% | 3646 |
|
|
2017
Q2 | $1.29M | Sell |
24,632
-1,641
| -6% | -$76.4K | ﹤0.01% | 3531 |
|
|
2017
Q1 | $1.19M | Buy |
26,273
+4,758
| +22% | +$212K | ﹤0.01% | 3616 |
|
|
2016
Q4 | $814K | Buy |
21,515
+6,670
| +45% | +$252K | ﹤0.01% | 3850 |
|
|
2016
Q3 | $561K | Buy |
14,845
+2,669
| +22% | +$58.9K | ﹤0.01% | 3886 |
|
|
2016
Q2 | $214K | Buy |
12,176
+4,186
| +52% | +$67.8K | ﹤0.01% | 4373 |
|
|
2016
Q1 | $97K | Buy |
7,990
+1,068
| +15% | +$16.9K | ﹤0.01% | 4852 |
|
|
2015
Q4 | $168K | Sell |
6,922
-20,439
| -75% | -$477K | ﹤0.01% | 4569 |
|
|
2015
Q3 | $485K | Sell |
27,361
-2,439
| -8% | -$44.2K | ﹤0.01% | 3967 |
|
|
2015
Q2 | $527K | Sell |
29,800
-5,266
| -15% | -$96.5K | ﹤0.01% | 4058 |
|
|
2015
Q1 | $1.1M | Buy |
35,066
+29,210
| +499% | +$847K | ﹤0.01% | 3469 |
|
|
2014
Q4 | $171K | Buy |
5,856
+5,372
| +1,110% | +$136K | ﹤0.01% | 4499 |
|
|
2014
Q3 | $10K | Sell |
484
-264
| -35% | -$5.21K | ﹤0.01% | 5596 |
|
|
2014
Q2 | $19K | Buy |
748
+248
| +50% | +$4.3K | ﹤0.01% | 5404 |
|
|
2014
Q1 | $11K | Buy |
+500
| New | +$10.1K | ﹤0.01% | 5384 |
|
Wells Fargo's AERI Position: Q4 2022 in Review
Wells Fargo sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 169,586 shares — an estimated $2.57M sold.
Wells Fargo first reported a position in AERI in Q1 2014 and held it in 35 quarters. The position peaked at $2.57M in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Wells Fargo reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Wells Fargo sold 169,586 Aerie Pharmaceuticals shares in Q4 2022, an estimated $2.57M.
- Wells Fargo first reported a position in Aerie Pharmaceuticals in Q1 2014 and held it in 35 quarters.
- Wells Fargo's Aerie Pharmaceuticals position peaked at $2.57M in Q3 2022.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Wells Fargo's 13F filing for Q4 2022, filed 13 Feb 2023.